S-1/LV One Week on and One Week Off Regimen in Advanced Hepatocellular Carcinoma (HCC)

Inclusion Criteria: * Male or female, 70 years \> Age \> 18 years * Patient with unresectable primary hepatocellular carcinoma * Child-Pugh Class A or B, without ascites * ECOG score 0 * At least one tumor nodule can be evaluated by CT or MRI * Can take medicine orally * Expected survival time not less than 12 weeks * Women of childbearing potential must have a negative pregnancy test performed within 7 days prior to enrolling in this portion of the study During the trial and 4 week after the trial, must take contraception * Patients must be: * Hemoglobin \> 9.0g/dl * ANC \> 1.5×109/L * Platelet ≥ 60×109/L * Total bilirubin \< 3mg/dl * ALT or AST \< 5 X ULN * ALP \< 4 X ULN * PT-INR \< 2.3 * Patients who is taking Warfarin , should be tested every week till getting stable INR * Serum creatinine \< 1.5 X ULN * Serum amylase and lipase \< 2 X ULN Exclusion Criteria: * Known or suspected allergy to any agent given in association with this trial * Local treatment within 4 weeks prior to start of study drug * History of any heart disease * History of HIV infection except for HBV and HCV * Active clinically serious infections (\> 2 NCI-CTC Version 3.0) * Clinically significant gastrointestinal bleeding within 4 weeks prior to study entry. * Embolization or infarction such as transient ischemic disease, deep vein thrombosis, pulmonary embolization within 6 months prior to study entry * Previous malignancy (except for cervical carcinoma in situ, adequate treated basal cell carcinoma, or superficial bladder tumors \[Ta, Tis and T1\], early gastric cancer, or other malignancies curatively treated \> 3 years prior to entry * Extrahepatic tumor spread which affects patient's prognosis, such as bony metastasis or brain metastasis * Hydrothorax， ascites and hydropericardium need to drain * Serious diarrhea * Combined with serious pulmonary diseases, such as interstitial pneumonia, pulmonary fibrosis and serious pulmonary emphysema * Serious complication,such as intestinal obstruction,renal insufficiency, hepatic insufficiency and cerebrovascular disorders * Pregnant or breast-feeding * Any condition that is unstable or could jeopardize the safety of the patient and its compliance in the study, in the investigator's judgment. * Gastrointestinal disease that may affect to the absorption of drug or pharmacokinetics. * Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in this study * Patients unable to swallow oral medications.